# A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms

> **NCT07234045** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 30 (estimated)

## Conditions studied

- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Relapsed/Refractory B-cell ALL

## Interventions

- **DRUG:** CAR T cells chimeric antigenreceptor cells

## Key facts

- **NCT ID:** NCT07234045
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-30
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07234045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07234045, "A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07234045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*